David Tanner

David Tanner is currently working as an Associate Scientist II at Ascidian Therapeutics since May 2022. Prior to this role, David worked as a Research Assistant at Liau Lab from June 2019 to May 2022, where David utilized CRISPR-Cas9 mutagenesis screens to study gain-of-function mutations in DNA methyltransferases and their protein partners. David also has experience as a Medical Laboratory Technologist at QLabs Inc from April 2020 to January 2021, conducting COVID-19 diagnostic testing. Additionally, David served as an Intern at the United States Senate in January 2020, tracking economic development grants in West Virginia. David holds a degree in Molecular and Cellular Biology from Harvard University.